ANTIMICROBIAL-RESISTANT GRAM-NEGATIVE INFECTIONS IN NEONATES: BURDEN OF DISEASE AND CHALLENGES IN TREATMENT

Laura Folgori[1]; Julia Bielicki[1,2]; Paul T. Heath[1]; Mike Sharland[1]

[1] Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London SW17 0RE, UK

[2] Paediatric Pharmacology, University Children's Hospital Basel, Spitalstrasse 33 4056, Basel, Switzerland

Corresponding Author: Laura Folgori

Mailing address: St George's University of London, Jenner Wing, Level 2, Room 2.215E, Cranmer Terrace, London, SW17 0RE, United Kingdom

e-mail address: lfolgori@sgul.ac.uk

Telephone number: +44 20 87254851

Fax number: +44 20 87250716

ABSTRACT

Purpose of review. This review summarises the main challenges of antimicrobial resistance (AMR) in the neonatal population with a special focus on multidrug-resistant (MDR) Gram-negative (GN) pathogens.

Recent findings. MDR-GN bacteria are a great concern in the neonatal population, with a worldwide rise in the reported incidence and with very limited therapeutic options. Extended-Spectrum β-Lactamase (ESBL) and Carbapenem-Resistant *Enterobacteriaceae* (CRE) have been reported as responsible for NICU outbreaks. Hospital data from low/middle-income countries show high proportions of isolates from neonates resistant to the WHO first-line and second-line recommended treatments. The spread of CRE has resulted in old antibiotics, such as colistin and fosfomycin, to be considered as alternative treatment options, despite the paucity of available data on safety and appropriate dosage.

Summary. Improved global neonatal AMR surveillance programmes including both epidemiology and clinical outcomes are critical for defining the burden and designing interventions. The optimal empiric treatment for neonatal sepsis in settings of high rates of AMR is currently unknown. Both strategic trials of older antibiotics and regulatory trials of new antibiotics are required to improve clinical outcomes in MDR-GN neonatal sepsis.

INTRODUCTION

Maternal and child deaths have halved worldwide over the past two decades [1]. However, neonatal mortality has remained unacceptably high, with an estimated 2.9 million deaths in newborns within the first 28 days of life every year. Among them, nearly a quarter is directly due to infectious causes (23%), with neonatal sepsis accounting for 15% [1]. Severe bacterial infections (SBI) in neonates account for about 3% of all disability-adjusted life years (DALY) [2]. Infection-attributable deaths, together with survivors of severe sepsis in the neonatal period, contribute largely to the global burden of disease.

Appropriate empirical treatment of SBI is crucially important in reducing mortality. However, it requires knowledge of the relative proportions of causative organisms at a local level as well as their resistance patterns collected using standardised methods. Multidrug-resistant (MDR) pathogens are now a challenge in both high-income (HIC) and low/middle-income countries (LMIC) [3]. Neonates admitted to Neonatal Intensive Care Units (NICU), especially premature infants, have been identified to be at high-risk for the selection and transmission of MDR pathogens. Recently, the first estimate of neonatal deaths attributable to resistant sepsis has been published, with antimicrobial resistance (AMR) potentially responsible for around 30% of all global neonatal sepsis deaths [4**].

This review summarises the main challenges of AMR in the neonatal population with a special focus on MDR Gram-negative (GN) pathogens.

GLOBAL EPIDEMIOLOGY AND CLINICAL IMPACT OF AMR IN NEONATES

Historically, the main resistant pathogens encountered in the hospital setting were Gram-positive bacteria. Among them, methicillin-resistant *Staphylococcus aureus* (MRSA) was a critically important pathogen in the NICU population, being associated with both endemic and epidemic infections [5].

Enterococci spp. are less-frequent, however, ampicillin-resistant and, more recently, vancomycin-resistant enterococci have been described in NICUs [6*].

Currently, it is MDR Gram-negative bacteria that are the greatest concern in the neonatal population, with a worldwide rise in the reported incidence and with very limited therapeutic options [7]. AMR among the *Enterobacteriaceae* represents a major problem in both healthcare-associated and community-acquired neonatal infections.

Extended-Spectrum β-Lactamase (ESBL)–Producing *Enterobacteriaceae*

The ESBLs are the result of a single nucleotide polymorphism in the *blaSHV* gene producing a family of enzymes able to hydrolyse the β-lactam ring [8]. There are many phenotypic and genetic differences among β-lactamases, with a common result that β-lactam antibiotics, such as penicillins, cephalosporins, and monobactams, are inactivated, leading to ineffective therapy. ESBLs are inhibited by β-lactam inhibitors (clavulanic acid, tazobactam, and sulbactam) [9]. β-lactamase genes are mostly carried on mobile genetic elements, frequently harbouring other resistance genes conferring resistance to other antibiotic classes [10]. The most common ESBLs are members of the SHV, TEM, and CTX-M (Ambler Class A) families (Table 1) [9].

Recently, many studies have been conducted globally on the prevalence of both community- and hospital-acquired ESBL-infections in neonates. ESBL-producing *Enterobacteriaceae* have been responsible for an increasing number of NICU outbreaks [11-15*].

Data from HIC showed a consistent rise in the rate of ESBL-positive isolates among neonatal units. A two-centre case–control study of children aged 0-17 years conducted in the US showed that 11/30 ESBL-producing isolates were in babies on NICU [10]. European data from the ARPEC study reported rates of resistance to 3rd-generation cephalosporins between 6.6 and 39.5% among *Enterobacteriaceae* in children less than 1 year [16]. A study conducted in Taiwan on 393 cases of GN

bacteraemia in NICU patients showed that the most frequent mechanism of resistance was ESBL-production that accounted for 67.1% of MDR strains [17]. MDR-GN bacteraemia was associated with a poorer outcome, with significantly higher rates of complications and overall case fatality. Another case-control analysis conducted in Taiwan between 2001 and 2012 reported that 14.2% of all neonatal GN late-onset sepsis were due to ESBL-producing strains (62.3% of *Klebsiella* spp, 20.8% of *Echerichia coli*, and 16.9% of *Enterobacter* spp). The SHV-type ESBLs were the most prevalent among these patients (67% of ESBLs), with most strains being genetically unrelated. In this study, neonates infected with ESBL-GN strains had higher rates of infectious complications (p = 0.008) and adverse outcomes (p=0.049) compared to non-ESBLs [18].

Although ESBL-producing *Enterobacteriaceae* are of global concern, they represent an even greater burden in LMIC. Asian studies showed a global rise in rates of ESBLs among hospitalised neonates. Data from a recent Indian study showed that 87% of *E. coli* isolated from septic neonates were ESBL-producers. CTX-M-15 was the most commonly identified ESBL (81%), reflecting its global dissemination [14]. The rates of β-lactamase production reported in 103 neonates in a referral hospital in Iran was 95.5% among *Klebsiella pneumoniae* and 78.6% among *E. coli* isolates. Infections caused by ESBL-producing pathogens were associated with longer hospital stay [13].

The same trend was highlighted in studies from South America, where an overall rate of 73.3% of ESBL-producers was identified in Peru among neonates infected with *K. pneumoniae*, with CTX-M-15 and CTX-M-2 the most commonly detected ESBLs [19]. Another study in Venezuela described the first nosocomial outbreak of ESBL-producing *Enterobacter ludwigiian* in neonates [12].

ESBL outbreaks in NICUs have been associated with suboptimal hygiene standards, with understaffing reported as a major risk factor [15*]. In non-outbreak settings, variables independently associated with ESBL infections in neonates included prematurity, low birth weight, prolonged hospitalization, invasive devices, and previous antibiotic use [8].

Carbapenem-Resistant *Enterobacteriaceae* (CRE)

The use of carbapenems has increased worldwide during the last decade due to the spread of ESBL-producing pathogens. Carbapenemases genes have been recently identified on mobile genetic elements, therefore favouring both person-to-person and species-to-species spread. Dynamics of spread and associated-resistance phenotypes vary according to different resistance determinants [20**]. Molecular classification of carbapenemases includes Ambler class A, B, and D, distinguished by the site of the hydrolytic mechanism (Table 1) [21].

Various studies have been published recently on the geographical expansion of CRE worldwide. After the global dissemination of *K. pneumoniae* carbapenemase (KPC)-producers, OXA-48 and New Delhi metallo-β-lactamase (NDM)-positive strains are now increasingly being reported [22]. However, limited data have been published on the epidemiology of CRE infections in the neonatal population, and the available data is largely limited to case reports or small case series. Nosocomial outbreaks have been reported in NICUs, and the geographic distribution is broadly comparable with data reported in adults [23]. It is unclear at present whether ESBL and CRE prevalence on neonatal units broadly reflects national resistance patterns or neonatal unit specific resistance profiles.

The majority of reports on the dissemination of CRE among the neonatal population in the last years has been published from South-East Asia and Western Pacific Regions. An outbreak of NDM-1-producing *K. pneumoniae* was recently reported in the neonatal ward of a teaching hospital in mainland China [24]. The isolates were shown to be clonally related and harboured a sequence type 17. The first *blaNDM-1*-positive *K. pneumoniae* in China was isolated in 2012. Since then, a number of reports have been published showing a continuous spread of *blaNDM-1*. In other areas of NDM endemicity, such as India, NDM-1 has been the predominant carbapenemase among neonates. In a 5-year study on neonatal sepsis in a tertiary care NICU in Kolkata, India, NDM-1 was identified in 14% of the 105 isolates, and was the only carbapenemase detected [25]. The same trend in the same hospital was highlighted in another 7-year study on carbapenem-resistant *Acinetobacter baumannii*

causing neonatal sepsis. Again, *blaNDM–1* was the major contributor to carbapenem-resistance [26]. Another *K. pneumoniae* sepsis outbreak described in a NICU in central India reported that all the isolates were positive for *blaNDM-1* with co-association of *blaCTX-M-15* [27]. The first study using whole-genome sequencing to characterise an extended outbreak caused by carbapenem-resistant *K. pneumoniae* in a neonatal unit in Nepal revealed that the case clusters were all caused by a single NDM *K. pneumoniae* with a conserved set of four plasmids, one carrying *blaNDM-1* gene [28]. In this study, the mortality rate among infected neonates was 64% (16/25).

Relatively few data has been published on the epidemiology of neonatal CRE in the African region, mainly from the North African countries. A large study conducted on 1,287 newborns in Morocco showed that 34 out of 157 isolated *Enterobacteriaceae* were carbapenemase-producing, with OXA-48 the predominant type [29]. However, no statistically significant difference in mortality was shown between neonates infected with CRE and non carbapenem-resistant strains.

Data from neonatal units in Europe and the US generally reflect the distribution of CRE in adults. A recent study published in Italy on a national cohort of 69 children infected or colonised with CRE confirmed the endemic role of the KPC carbapenemase in Southern Europe and the Mediterranean region, with 61.4% of CRE being KPC-producing and 13.6% harbouring the OXA-48 type [30].

Plasmid-mediated Colistin-Resistant Enterobacteriaceae

With the global increase in the prevalence of CRE, polymyxins have become a last-resort treatment option, with an increase in the human consumption of colistin and an inevitable risk of emerging resistance. Recently, the emergence of plasmid-mediated *mcr-1* gene conferring colistin-resistance has become a great challenge to public health [31]. This gene has been identified firstly in animals and humans in China, but is now being reported in several other countries [32]. New agents effective

against MDR-GN pathogens are lacking, and the impact of mobile colistin resistance genes on global health cannot be underestimated.

The first report published in 2016 on the detection of *mcr-1* gene in *K. pneumoniae* and *E. coli* isolated from an infant with diarrhoea in China raised huge concerns [33**]. Due to the very limited therapeutic options, the emergence of *mcr-1*-positive isolates in neonates represents an enormous challenge. Furthermore, the simultaneous isolation of this gene in two different pathogens from the same patient is likely to suggest horizontal transmission.

CHALLENGES IN AVAILABLE TREATMENTS

Hospital data from LMIC reported in a recent systematic review shows that nearly half of pathogens causing SBI in neonates are resistant to the WHO first-line recommended regimen of ampicillin (or penicillin) and gentamicin, and to the second-line treatment with 3rd-generation cephalosporins [4**, 34-36]. These findings could potentially have significant implications for global antibiotic recommendations in neonatal settings [37-38*-39]. The current *WHO's Pocketbook of Hospital Care for Children* provides the same empiric guidance for probable SBI in both early-onset and late-onset sepsis in both the community and hospital setting. However, the risks of MDR-GN sepsis may vary considerably between early-onset in the rural population and late-onset nosocomial infections in large neonatal units.

Babies are particularly at risk for adverse outcomes from sepsis due to MDR-*Enterobacteriaceae*, with few available effective antimicrobials approved for neonatal use and the pipeline for novel antibiotics in advanced development limited (Table 2).

The role of β-lactam–β-lactamase inhibitors (BL/BLIs) for the treatment of ESBL infections is still controversial since many organisms have been shown to produce multiple ESBLs simultaneously, therefore reducing the effectiveness of the inhibitor. The available literature is limited to

observational studies where BL/BLIs have been compared with carbapenems in neonates with ESBL-producing *Enterobacteriaceae*, showing no difference in clinical outcomes [42]. Carbapenems have become the treatment of choice for neonatal ESBL-infections, and should be used as monotherapy since no evidence of benefit from addition of an aminoglycoside has been demonstrated [40].

The optimal treatment for CRE infections in adults has not been defined yet due to the lack of large randomised studies evaluating different therapeutic approaches. Small case series seem to support the use of combination therapy to significantly reduce mortality [22].

The emergence and spread of CRE among NICU patients has led to old antibiotics, such as colistin and fosfomycin, to be reconsidered, even if the increasing prevalence of colistin-resistant CRE is of high concern [32, 33**, 43].

Colistin is increasingly used in the neonatal population. However, few studies have been published about its use in neonatal sepsis, and none of them focussed specifically on infections caused by CRE. Colistin is associated with renal toxicity, with significant rates of acute kidney injury reported in adults [20**]. In a retrospective study on 12 neonates infected with MDR-GN bacteria, the intravenous treatment with colistin seemed to be safe and efficacious, including for preterm babies [44]. Another retrospective study on 21 neonates treated with colistin for MDR *Acinetobacter* sepsis showed a surviving rate of 91%, with no renal impairment being documented [45]. A similar report on preterm neonates with nosocomial sepsis caused by *A. baumannii* showed a recovery rate of 81% in babies receiving IV colistin, with acute kidney injury reported in 19% [46]. A recent PK study on 7 critically ill neonates with GN infections highlighted that a single IV dose of colistin at the currently recommended dosage resulted in suboptimal plasma concentrations [47].

There is little experience of using fosfomycin in neonates, and it should be considered as a final-resort option for extensively-drug resistant GN [48]. This drug has a broad-spectrum of bactericidal activity and is active against the majority of CRE isolates, with the advantage that it achieves excellent concentrations in urine, plasma, bronchoalveolar and cerebrospinal fluid, with low rates of

toxicity [40]. Resistance to fosfomycin can develop rapidly if used as monotherapy, but if combined with other agents the chance of developing resistance is limited [42].

Tigecycline is active against many difficult-to-treat MDR-GN. However, due to the possible effects on bone growth, the use in neonates could only be justified when other effective antibiotics are not available [40, 42, 48].

At the moment, 37 new antibiotics are listed on the Pew Charitable Trusts Antibiotic Pipeline, with few of them, such as aztreonam-avibactam, carbavance (vaborbactam+meropenem) and plazomicin, specifically targeting infections caused by CRE [49]. However, there is only one study currently ongoing on the safety and pharmacokinetics of carbavance in children that includes neonates [50].

CONCLUSIONS AND FUTURE PERSPECTIVES

Standardised global surveillance programmes collecting neonatal AMR data including risk factors and clinical outcomes are critical to allow benchmarking and design interventions. Studies published so far reported conflicting data about the relationship between currently-defined MDR isolates and neonatal mortality. This should be addressed properly through prospective studies focussing on clinical impact of AMR in neonatal sepsis.

It should be noted that although the increasing emphasis on in-hospital births in LMIC may led to improve neonatal outcomes in terms of birth complications and stillbirths, this may be at the expense of increased exposure of babies to highly-resistant hospital flora, and to the subsequent spread of AMR.

The impact of different risk factors at both baby- and hospital-level is still debated. Due to the paucity and high heterogeneity of available studies, firm conclusions on the correlation between GNB colonisation and BSI in neonates cannot be made at the moment, with the few existing data too weak to be used for clinical decision-making.

The optimum choice of drug, dose, and duration to treat neonatal sepsis in settings of high resistance to WHO first-line empirical therapy is still unknown. The evidence-base for the use of new (and older) antibiotics needs to be developed through both strategic and regulatory clinical trials in order to define the best available treatment and improve the management of these severe infections in neonates, especially in LMIC setting. Harmonisation of surveillance definitions, including age groups and outcome measures, would also allow pooling data from different datasets.

Key points:

• ESBL-producing and Carbapenem-resistant *Enterobacteriaceae* are of great concern in the neonatal population, with a worldwide rise in the reported incidence and with very limited therapeutic options.

• Alarming proportions of pathogens causing SBI in neonates are now reported to be resistant to the WHO first-line and second-line recommended treatments.

• The spread of CRE among NICU patients has resulted in the increasing use of old antibiotics in neonates, despite the paucity of available data on safety and appropriate dosage.

• The evidence-base for the use of new (and older) antibiotics needs to be developed through both strategic and regulatory clinical trials in order to define the best available treatment for MDR-GN infections in neonates.

Conflicts of interests: the authors have no conflict of interests relevant to this work.

Table 1: Summary of resistance mechanisms and phenotypes for clinically important β-lactamases according to Ambler classification

Ambler classification	Resistance mechanism	Representative enzymes	Genetic basis	Relevant organisms	Substrates
Class A	ESBLs	TEM, SHV, CTX-M	Plasmid	*Escherichia coli, Klebsiella spp, Proteus mirabilis*	Penicillins, 3rd gen-cephalosporins
	Carbapenemases	KPC	Plasmid	*Klebsiella pneumoniae, E. coli, Klebsiella oxytoca, Serratia marcescens, Enterobacter spp, Citrobacter freundii*	All β-lactams
Class B	Carbapenemases, metallo-β-lactamases	VIM, IMP, NDM-1	Plasmid	*K. pneumoniae, E. coli, K. oxytoca, S. marcescens, Enterobacter spp, C. freundii*	All β-lactams, except monobactams
Class C	Cephalosporinases	AmpC	Chromosomal	*K. pneumoniae, E. coli, Enterobacter spp, Salmonella enteritidis, C. freundii, S. marcescens*	Cephamycins, 3rd gen-cephalosporins
Class D	Carbapenemases	OXA	Plasmid	*Acinetobacter baumannii, Pseudomonas aeruginosa, E. Coli, K. Pneumoniae, P. Mirabilis, C. freundii*	All β-lactams

Table 2: Currently available treatments for Gram-negative neonatal sepsis

Drug	Recommended IV dosage*		CSF penetration	Notes
	0-6 days	7-28 days		
Ampicillin	30–60 mg/kg 12 hourly	30–60 mg/kg 6–8 hourly	Poor if meninges are not inflamed	High doses can be administered because of low toxicity
Amoxicillin	50–100 mg/kg 12 hourly	50–100 mg/kg 8 hourly	Poor if meninges are not inflamed	High doses can be administered because of low toxicity
Piperacillin-tazobactam	90 mg/kg 8 hourly	90 mg/kg 8 hourly	Poor	**Active against most ESBL-producing Enterobacteriaceae but limited data in neonates**
Cefotaxime	25–50 mg/kg 12 hourly	25–50 mg/kg 6–8 hourly	Adequate when meninges are inflamed	High doses can be administered because of low toxicity
Ceftazidime	25–50 mg/kg once daily	25–50 mg/kg 8–12 hourly	Adequate when meninges are inflamed	High doses can be administered because of low toxicity
Meropenem	20-40 mg/kg 12 hourly	20-40 mg/kg 8 hourly	Adequate	**Active against ESBL-producing Enterobacteriaceae**
Gentamicin	5 mg/kg 36 hourly	5 mg/kg 24 hourly	Poor	TDM** required
Ciprofloxacin	10 mg/kg 12 hourly	10 mg/kg 12 hourly	Good	Consider TDM in serious infections
Colistin	25,000 units/kg 8 hourly	25,000 units/kg 8 hourly	Inadequate	TDM recommended. **Active against Carbapenem-resistant Enterobacteriaceae (CRE)**
Fosfomycin	50 mg/kg 12 hourly	100 mg/kg 12 hourly	Good	To use in combination to avoid development of resistance. **Active against ESBL-producing Enterobacteriaceae and most CRE**
Tigecycline	Insufficient data available		Inadequate	**Active against ESBL-producing Enterobacteriaceae and CRE**

Modified from: Gray JW et al [40]. *Dosages according to those recommended in the British National Formulary for Children (BNFC) [41]. **TDM: Therapeutic Drug Monitoring

REFERENCES

* of special interest

** of outstanding interest

1.   Lawn JE, Blencowe H, Oza S, et al. Every Newborn: progress, priorities, and potential beyond survival. Lancet 2014; 384(9938): 189-205.

2.   Seale AC, Blencowe H, Manu AA, et al. Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: a systematic review and meta-analysis. Lancet Infect Dis 2014; 14(8): 731-41.

3.   Abdula N, Macharia J, Motsoaledi A, et al. National action for global gains in antimicrobial resistance. Lancet 2016; 387(10014): e3-5.

**4.   Laxminarayan R, Matsoso P, Pant S, et al. Access to effective antimicrobials: a worldwide challenge. Lancet 2016; 387(10014): 168-75.

This paper reports the first estimated number of neonatal deaths attributable to antimicrobial resistance in the five countries accounting for 52% of global neonatal sepsis deaths. The quantification of the disease burden may contribute to design properly targeted interventions.

5.   Cailes B, Vergnano S, Kortsalioudaki C, et al. The current and future roles of neonatal infection surveillance programmes in combating antimicrobial resistance. Early Hum Dev 2015; 91(11): 613-8.

*6.   Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health 2016; 4(10): e752-e60.

This paper provides data for incidence, profile of organisms, and antimicrobial resistance from a large cohort on neonates in Delhi, India. The high fatality rate and the alarming proportion of MDR

pathogens causing neonatal sepsis highlight the gaps in the current knowledge, and the need to conduct targeted studies to understand pathogenesis and design strategies to prevent sepsis-related mortality in neonates from low- and middle-income countries.

7.   Doare KL, Bielicki J, Heath PT, Sharland M. Systematic review of antibiotic resistance rates among Gram-negative bacteria in children with sepsis in resource-limited Countries. J Pediatric Infect Dis Soc 2015; 4(1): 11-20.

8.   Lukac PJ, Bonomo RA, Logan LK. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat. Clin Infect Dis 2015; 60(9): 1389-97.

9.   Murray TS, Peaper DR. The contribution of extended-spectrum beta-lactamases to multidrug-resistant infections in children. Curr Opin Pediatr 2015; 27(1): 124-31.

10.   Logan LK, Meltzer LA, McAuley JB, et al. Extended-Spectrum beta-Lactamase-Producing Enterobacteriaceae Infections in Children: A Two-Center Case-Case-Control Study of Risk Factors and Outcomes in Chicago, Illinois. J Pediatric Infect Dis Soc 2014; 3(4): 312-9.

11.   Jain S, Gaind R, Kothari C, et al. VEB-1 extended-spectrum beta-Lactamase producing multidrug-resistant Proteus mirabilis sepsis outbreak in a neonatal intensive care unit in India: Clinical and diagnostic implications. JMM Case Reports 2016; 3(4).

12.   Flores-Carrero A, Labrador I, Paniz-Mondolfi A, et al. Nosocomial outbreak of extended-spectrum beta-lactamase-producing Enterobacter ludwigii co-harbouring CTX-M-8, SHV-12 and TEM-15 in a neonatal intensive care unit in Venezuela. J Glob Antimicrob Resist 2016; 7: 114-8.

13.   Peirovifar A, Rezaee MA, Gharehbaghi MM. Prevalence of multidrug resistant extended-spectrum beta-lactamase producing Gram-negative bacteria in neonatal sepsis. IJWHR 2014; 2(3): 138-45.

14.   Roy S, Datta S, Das P, et al. Insight into neonatal septicaemic Escherichia coli from India with respect to phylogroups, serotypes, virulence, extended-spectrum-beta-lactamases and association of ST131 clonal group. Epidemiol Infect 2015; 143(15): 3266-76.

*15.   Stapleton PJ, Murphy M, McCallion N, et al. Outbreaks of extended spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units: a systematic review. Arch Dis Child Fetal Neonatal Ed 2016; 101(1): F72-8.

Systematic review of outbreaks caused by ESBL-producing Enterobacteriaceae in NICU worldwide. This paper summarises the epidemiology, outcomes and risk factors associated with ESBL colonisation and infections in neonates, as well as the interventions put in place to resolve them.

16.   Bielicki JA, Lundin R, Sharland M. Antibiotic resistance prevalence in routine bloodstream isolates from children's hospitals varies substantially from adult surveillance data in Europe. Pediatr Infect Dis J 2015; 34(7): 734-41.

17.   Tsai MH, Chu SM, Hsu JF, et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. Pediatrics 2014; 133(2): e322-e9.

18.   Tsai MH, Lee IT, Chu SM, et al. Clinical and molecular characteristics of neonatal extended-spectrum beta-lactamase-producing Gram-negative bacteremia: A 12-year case-control-control study of a referral center in Taiwan. PLoS ONE 2016; 11(8):e0159744.

19.   Garcia C, Astocondor L, Rojo-Bezares B, et al. Molecular Characterization of Extended-Spectrum beta-Lactamase-Producer Klebsiella pneumoniae Isolates Causing Neonatal Sepsis in Peru. Am J Trop Med Hyg 2016; 94(2): 285-8.

**20.   Chiotos K, Han JH, Tamma PD. Carbapenem-Resistant Enterobacteriaceae Infections in Children. Curr Infect Dis Rep 2016; 18(1): 2.

Comprehensive review of CRE infections in children, including clinical and molecular epidemiology, microbiologic diagnosis, antibiotic treatment options, and outcomes. This is one of the two published

reviews on CRE infections in paediatrics, and it is particularly valuable because it discusses in details pros and cons of the different available drugs.

21.   Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17(10): 1791-8.

22.   Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20(9): 862-72.

23.   Logan LK. Carbapenem-resistant Enterobacteriaceae: an emerging problem in children. Clin Infect Dis 2012; 55(6): 852-9.

24.   Zhang X, Li X, Wang M, et al. Outbreak of NDM-1-producing Klebsiella pneumoniae causing neonatal infection in a teaching hospital in mainland China. Antimicrob Agents Chemother 2015; 59(7): 4349-51.

25.   Datta S, Roy S, Chatterjee S, et al. A five-year experience of carbapenem resistance in Enterobacteriaceae causing neonatal septicaemia: predominance of NDM-1. PLoS ONE 2014; 9(11): e112101.

26.   Chatterjee S, Datta S, Roy S, et al. Carbapenem resistance in Acinetobacter baumannii and other Acinetobacter spp. causing neonatal sepsis: Focus on NDM-1 and its linkage to ISAba125. Front Microbiol. 2016; 7:1126.

27.   Khajuria A, Praharaj AK, Kumar M, et al. Multidrug resistant NDM-1 metallo-beta-lactamase producing Klebsiella pneumoniae sepsis outbreak in a neonatal intensive care unit in a tertiary care center at central India. Indian J Pathol Microbiol 2014; 57(1): 65-8.

28.   Stoesser N, Giess A, Batty EM, et al. Genome sequencing of an extended series of NDM-producing Klebsiella pneumoniae isolates from neonatal infections in a Nepali hospital characterizes the extent of community- Versus hospital- associated transmission in an endemic setting. Antimicrob Agents Chemother 2014; 58(12): 7347-57.

29.   Chabah M, Chemsi M, Zerouali K, et al. Healthcare-associated infections due to carbapenemase-producing Enterobacteriaceae: Bacteriological profile and risk factors. Med Mal Infect 2016; 46(3): 157-62.

30.   Montagnani C, Prato M, Scolfaro C, et al. Carbapenem-resistant Enterobacteriaceae Infections in Children: An Italian Retrospective Multicenter Study. Pediatr Infect Dis J 2016; 35(8): 862-8.

31.   Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16(2): 161-8.

32.   Ye H, Li Y, Li Z, et al. Diversified mcr-1-Harbouring Plasmid Reservoirs Confer Resistance to Colistin in Human Gut Microbiota. MBio 2016; 7(2): e00177.

**33.   Gu DX, Huang YL, Ma JH, et al. Detection of Colistin Resistance Gene mcr-1 in Hypervirulent Klebsiella pneumoniae and Escherichia coli Isolates from an Infant with Diarrhea in China. Antimicrob Agents Chemother 2016; 60(8): 5099-100.

The first report on the detection of mcr-1 gene in Enterobacteriaceae isolated from an infant in China. This paper raised huge concerns due to the actual absence of treatments for pan-drug resistant Gram-negatives in neonates. Furthermore, this represents the first case of a co-infection caused by two different bacteria both harbouring mcr-1 gene, therefore suggesting horizontal transmission.

34.   Downie L, Armiento R, Subhi R, et al. Community-acquired neonatal and infant sepsis in developing countries: efficacy of WHO's currently recommended antibiotics-systematic review and meta-analysis. Arch Dis Child 2013; 98(2): 146-54.

35.   Kabwe M, Tembo J, Chilukutu L, et al. Etiology, antibiotic resistance and risk factors for neonatal sepsis in a large referral center in Zambia. Pediatr Infect Dis J 2016; 35(7): e191-e8.

36.   Kumar S, Graham SM, Varman S, et al. Resistance of Bacterial Isolates from Neonates with Suspected Sepsis to Recommended First-Line Antibiotics in Fiji. Pediatr Infect Dis J 2015; 34(8): 915-6.

37.   Obiero CW, Seale AC, Berkley JA. Empiric Treatment of Neonatal Sepsis in Developing Countries. Pediatr Infect Dis J 2015; 34(6): 659-61.

*38.   Seale AC, Obiero CW, Berkley JA. Rational development of guidelines for management of neonatal sepsis in developing countries. Curr Opin Infect Dis 2015; 28(3): 225-30.

This paper discusses the challenges of managing neonatal sepsis in developing countries, and underlines the importance of conducting properly-designed clinical trials to define simplified treatments that would take into account the spread of antimicrobial resistance.

39.   Huynh BT, Padget M, Garin B, et al. Burden of bacterial resistance among neonatal infections in low income countries: how convincing is the epidemiological evidence? BMC Infect Dis 2015; 15: 127.

40.   Gray JW, Ubhi H, Milner P. Antimicrobial treatment of serious Gram-negative infections in newborns topical collection on pediatric infectious diseases. Curr Infect Dis Rep 2014; 16:400.

41.   BNF for children 2016-17. www.bnfc.org. Last accessed 20 December 2016.

42.   Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis 2014; 58(10): 1439-48.

43.   Singh SK, Gupta M. blaOXA-48 carrying clonal colistin resistant-carbapenem resistant Klebsiella pneumoniae in neonate intensive care unit, India. Microb Pathog 2016; 100:75-77.

44.   Tekgunduz KS, Kara M, Caner I, Demirelli Y. Safety and efficacy of intravenous colistin in neonates with culture proven sepsis. Iran J Pediatr 2015; 25(4):e453.

45. Al-lawama M, Aljbour H, Tanash A, Badran E. Intravenous Colistin in the treatment of multidrug-resistant Acinetobacter in neonates. Ann Clin Microbiol Antimicrob 2016; 15:8.

46. Alan S, Yildiz D, Erdeve O, et al. Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii. Am J Perinatol 2014; 31(12): 1079-86.

47. Nakwan N, Usaha S, Chokephaibulkit K, et al. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates. Pediatr Infect Dis J 2016; 35(11):1211-1214.

48. Tzialla C, Borghesi A, Serra G, et al. Antimicrobial therapy in neonatal intensive care unit. Ital J Pediatr 2015; 41:27.

49. Antibiotics Currently in Clinical Development. 2016. http://www.pewtrusts.org/~/media/assets/2016/05/antibiotics-currently-in-clinical-development.pdf. Last accessed 19 December 2016.

50. Dose-finding, Pharmacokinetics, Safety, and Tolerability of Meropenem-Vaborbactam in Pediatric Subjects With Serious Bacterial Infections. https://clinicaltrials.gov/ct2/show/NCT02687906?term=Carbavance&rank=4. Last accessed 19 December 2016.